15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering Mereo BioPharma Group PLC ADR, 2 rate it Buy or better, 3 sit at Hold, and 0 rate it Sell or worse, a hold consensus. The target range is very wide, $0.50 to $8.00 (about 16.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $3.13 sits 934% above the current $0.30. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.01 next quarter toward $-0.03 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Hold
Strong Buy00%
Buy240%
Hold360%
Sell00%
Strong Sell00%
Based on 5 analysts giving stock ratings to Mereo BioPharma Group PLC ADR.
As of Jul, 2 of 5 firms rate MREO a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
MREO EPS & revenue forecast
EPS · NEXT QUARTER
$-0.01
Range $-0.01 – $-0.01 · 5 analysts · -8% YoY
Next period, 5 analysts expect Mereo BioPharma Group PLC ADR to earn $-0.01 a share (range $-0.01 – $-0.01), versus $-0.01 a year earlier. Full-year consensus is $-0.03, growing to $-0.03 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 5 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $6.1M, rising to $14.6M next year.
Top analysts covering Mereo BioPharma Group PLC ADR
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MREO.
#1
Kristen Kluska
Cantor Fitzgerald · Rank #162
Buy
$7.00+2217.1% to target
Overall win rate
38%
+ Follow
#2
Gil Blum
Needham · Rank #298
Buy
$3.00+893.0% to target
Overall win rate
24%
+ Follow
#3
Julian Harrison
BTIG
Buy
$1.00+231.0% to target
Coverage
—
+ Follow
#4
PG
Priyanka Grover
JP Morgan
Hold
No targeton MREO
Coverage
—
+ Follow
#5
MR
Maury Raycroft
Jefferies
Hold
$0.50+65.5% to target
Coverage
—
+ Follow
MREO stock forecast FAQ
What is MREO's average 12-month price target?+
The 3 analysts with a live target average $3.13 for Mereo BioPharma Group PLC ADR over the next 12 months, ranging from a $8.00 high to a $0.50 low.
Is MREO stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 5 analyst ratings, 2 are Buy or Strong Buy, 3 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for MREO?+
The Street-high target is $8.00, and the Street-low is $0.50 (Jefferies). The average of all 3 active targets is $3.13.
How many Wall Street analysts cover MREO?+
5 analysts have an active rating on Mereo BioPharma Group PLC ADR, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering MREO?+
Among analysts who currently cover MREO, Kristen Kluska of Cantor Fitzgerald has the strongest overall Quantellect track record (Rank #162). Their current call is Buy with a $7.00 target.
What is Mereo BioPharma Group PLC ADR's projected EPS for next quarter?+
The consensus estimate is $-0.01 per share (range $-0.01 – $-0.01) across 5 analysts. Full-year EPS is projected at $-0.03, rising to $-0.03 the following year.
How much revenue is Mereo BioPharma Group PLC ADR expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $6.1M, growing to $14.6M next year.
Have analysts been upgrading or downgrading MREO lately?+
As of Jul, 2 of 5 firms rate MREO a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MREO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
